FDA Greenlights Once-Monthly Andembry in USA to Combat Hereditary Angioedema -

Read Time:1 Minute, 4 Second

The U.S. Food and Drug Administration (FDA) has approved Andembry (garadacimab-gxii) for the prevention of hereditary angioedema (HAE) attacks. This new treatment uniquely targets factor XIIa, a crucial component in the development of HAE.

Andembry is administered as a once-monthly injection, offering a convenient option for people living with HAE, a rare genetic disorder characterized by painful swelling in various parts of the body. Until now, most treatments focused on managing symptoms or acute attacks, rather than preventing them.

Significance of FDA Approval

The FDA’s approval of Andembry represents a significant advancement in care for HAE patients by:

Reducing the frequency and severity of HAE attacks
Providing a targeted, prophylactic approach
Improving quality of life through easier dosing schedules

According to the Mayo Clinic, HAE can be life-threatening if swelling compromises the throat or breathing passages, making prevention critically important.

Benefits of Andembry

Targeted Mechanism: Specifically inhibits factor XIIa to prevent attacks.
Convenient Dosing: Once-monthly injections improve adherence and patient comfort.
Enhanced Preventive Care: Provides healthcare providers a new tool to proactively manage HAE.

This approval highlights progress in therapies for rare diseases in the United States and encourages further research in HAE management.

Stay tuned to Questiqa USA for the latest updates on this and other healthcare advancements.